Quick Heal Technologies Ltd (IT - Software) — fundamental analysis, earnings data, and key metrics. PE: 157.0. ROE: 0.6%. This stock is not currently in the Nifty 500 momentum outperformers list.
Based on Q3 FY26 earnings • Updated Apr 18, 2026
What: Enterprise Revenue Share: 45% of 9M FY26 revenue
“4 years back, our Consumer business was 18% and our Enterprise business 20%. But over the last couple of quarters, now it is 60-40.”
What: New Order Value: ₹64 Cr
Impact: ₹64 Cr over 5 years
“INR 64 Cr Order received: 5-year fulfillment period for implementation of integrated cybersecurity solutions”
What: DPDP Market Potential: New market creation
“this law is much more comprehensive and guidelines are coming... scope for a product like data privacy product that we just launched”
What: Enterprise Revenue growth of 37.1% YoY
“Enterprise Revenue 37.1% YoY... Enterprise business continued to grow steadily, driven by strong partners, innovative product launches”
Earnings deceleration risks from management commentary
Trigger: The law is passed but implementation and enforcement guidelines are still pending.
Management view: Onboarding early adopters for POCs to be ready when enforcement begins.
Monitor: regulatory
Trigger: Changing consumer behavior and built-in OS security features reducing demand for standalone AV.
Impact: PAT impact: -21.2% YoY revenue hit in Consumer segment
Management view: Launching AntiFraud.AI to pivot from pure AV to broader digital protection.
Monitor: cyber
Key quotes from recent conference calls
“Having said that, in last couple of quarters, we are in the similar range of around INR 30 crores to INR 35 crores in a quarter [Previous R&D Expense Range guidance]”
“Positioning AntiFraud.AI to tackle the financial frauds... Focus towards maintaining our market share in AV segment [Initiative: AntiFraud.AI Launch]”
“that is something that will create a new market altogether for a product like complying for DPDP [Initiative: DPDP Compliance Products]”
“But then, of course, the law is still delayed. It's not yet completely implemented on the ground. [Risk (regulatory): MEDIUM]”
Headline numbers from the latest earnings call
Revenue
₹71.5 Cr
Why: Revenue growth was driven by a 37.1% increase in Enterprise revenue, offset by a 21.2% decline in the Consumer segment.
The company is seeing a structural shift as Enterprise revenue now matches Consumer revenue.
EBITDA
₹0.5 Cr
Why: EBITDA improved due to optimized R&D investments through automation and AI, despite a decline in high-margin consumer revenue.
Margins remain thin at 0.6% as the company transitions its business mix.
PAT
₹6.6 Cr
Why: PAT growth was significantly aided by a sharp increase in Other Income to ₹9.0 Cr compared to ₹4.9 Cr in the previous year.
The massive YoY percentage jump is due to a very low base of ₹0.1 Cr in Q3 FY25.
Other Highlights
• Order Book stands at ₹80 Cr+
• Deferred Revenue increased to ~₹20 Cr
• Received ₹64 Cr order for integrated cybersecurity solutions with a 5-year fulfillment period
Sub-sector-specific signals from the latest concall — each with management's stated reason for the change
Enterprise Revenue % of Total
45%
Why: Rapid growth in Seqrite business vs decline in Quick Heal consumer business.
Deferred Revenue
₹20 Cr
Why: Increased multi-year deal bookings in the Enterprise segment.
Order Book
₹80 Cr
Why: Strong traction in Government and Enterprise multi-year contracts.
R&D as % of Revenue
41.1%
Why: Management is optimizing R&D spend through AI and automation.
Enterprise Revenue Growth (YoY)
37.1%
Why: Driven by mid-market capture and new product launches.
Consumer Revenue Growth (YoY)
-21.2%
Why: Structural decline in the global consumer antivirus market.
Enterprise Cloud Revenue Mix
35%
Why: Increasing adoption of cloud-based security solutions over on-premise.
Enterprise Repeat Customer Rate
80%+
Why: High stickiness in enterprise cybersecurity contracts.
Forward-looking targets from management for Long-term
Capex Plan
₹179 Cr
Margins will certainly improve as the business grows.
₹179 Cr
Potential M&A or strategic acquisitions
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Apr 18, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
Quick Heal Technologies Ltd's latest quarterly results (Dec 2025) show
Quick Heal Technologies Ltd's current PE ratio is 157.0x.
Quick Heal Technologies Ltd's price-to-book ratio is 2.0x.
Quick Heal Technologies Ltd's fundamental strength based on key financial ratios
Quick Heal Technologies Ltd has a debt-to-equity ratio of N/A.
Quick Heal Technologies Ltd's return ratios over recent years
Quick Heal Technologies Ltd's operating cash flow is negative (FY2025).
Quick Heal Technologies Ltd currently does not pay a significant dividend (yield 0.00%).
Quick Heal Technologies Ltd's shareholding pattern (Mar 2026)
Quick Heal Technologies Ltd's promoter holding has decreased recently.
Quick Heal Technologies Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
Quick Heal Technologies Ltd has 4 key growth catalysts identified from recent earnings analysis
Quick Heal Technologies Ltd has 2 key risks worth monitoring
In Q3 FY26, Quick Heal Technologies Ltd's management highlighted
Quick Heal Technologies Ltd's management has provided the following forward guidance for Long-term
Quick Heal Technologies Ltd's most important sub-sector-specific KPIs from the latest concall
Based on quantitative research signals, here is why Quick Heal Technologies Ltd may be worth studying
Quick Heal Technologies Ltd investment thesis summary:
Quick Heal Technologies Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
